J,، A,، diabetes، insulin، Metab

Physical activity as a metabolic stressor. Am J Clin Nutr 72:512S-520S
54. Reaven GM 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
55. Ridker PM, Buring JE, Cook NR, Rifai N 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107:391-397
56. Rozita. F, Abbas. G-N, RR. K, Elahe. T-G, Mehdi. S 2010 The effect of exercise intensity on plasma and tissue acyl ghrelin concentrations in fasted rats. Regul Pept 165:133-137
57. Ghoddousi K AF, Ameli J. 2005 Role of physical activity on serum lipids Kowsar Medical Journal 1:64-59
58. Mayfield J 1998 Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physician 58:1355-1362, 1369-1370
59. Brown JE, Onyango DJ, Dunmore SJ 2007 Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett 581:3273-3276
60. Icks A, Trautner C, Haastert B, Berger M, Giani G 1997 Blindness due to diabetes: population-based age- and sex-specific incidence rates. Diabet Med 14:571-575
61. Zimmet P, Alberti KG, Shaw J 2001 Global and societal implications of the diabetes epidemic. Nature 414:782-787
62. Coughlan A, McCarty DJ, Jorgensen LN, Zimmet P 1997 The epidemic of NIDDM in Asian and Pacific Island populations: prevalence and risk factors. Horm Metab Res 29:323-331
63. Colditz GA, Willett WC, Rotnitzky A, Manson JE 1995 Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122:481-486
64. Vaxillaire M, Froguel P 2006 Genetic basis of maturity-onset diabetes of the young. Endocrinol Metab Clin North Am 35:371-384, x
65. Hamilton-Shield JP 2007 Overview of neonatal diabetes. Endocr Dev 12:12-23
66. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA 1998 IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 102:516-526
67. Oshima H, Taketo MM, Oshima M 2006 Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E2 in the islets. J Biol Chem 281:29330-29336
68. Ou D, Metzger DL, Wang X, Huang J, Pozzilli P, Tingle AJ 2002 TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia 45:1678-1688
69. Alba A, Puertas MC, Carrillo J, Planas R, Ampudia R, Pastor X, Bosch F, Pujol-Borrell R, Verdaguer J, Vives-Pi M 2004 IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice. J Immunol 173: 6667-6675
70. Gerich JE 1998 The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 19:491-503
71. Chen L, Magliano DJ, Balkau B, Colagiuri S, Zimmet PZ, Tonkin AM, Mitchell P, Phillips PJ, Shaw JE 2010 AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust 192:197-202
72. Venables MC, Jeukendrup AE 2009 Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. Diabetes Metab Res Rev 25 Suppl 1:S18-23
73. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A 2007 Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 116:1081-1093
74. Marwick TH, Hordern MD, Miller T, Chyun DA, Bertoni AG, Blumenthal RS, Philippides G, Rocchini A 2009 Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:3244-3262
75. Snowling NJ, Hopkins WG 2006 Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 29:2518-2527
76. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
77. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V 2006 The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289-297
78. Dunstan DW, Puddey IB, Beilin LJ, Burke V, Morton AR, Stanton KG 1998 Effects of a short-term circuit weight training program on glycaemic control in NIDDM. Diabetes Res Clin Pract 4: 53-61
79. Hordern MD, Dunstan DW, Prins JB, Baker MK, Singh MA, Coombes JS 2012 Exercise prescription for patients with type 2 diabetes and pre-diabetes: A position statement from Exercise and Sport Science Australia. J Sci Med Sport 15:25-31
80. Spiegelman BM, Choy L, Hotamisligil GS, Graves RA, Tontonoz P 1993 Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem 268:6823-6826
81. Paulauskis JD, Sul HS 1989 Hormonal regulation of mouse fatty acid synthase gene transcription in liver. J Biol Chem 264:574-577
82. Vazquez-Vela ME, Torres N, Tovar AR 2008 White adipose tissue as endocrine organ and its role in obesity. Arch Med Res 39:715-728
83. Gesta S, Tseng YH, Kahn CR 2007 Developmental origin of fat: tracking obesity to its source. Cell 131:242-256
84. Kawate R, Talan MI, Engel BT 1994 Sympathetic nervous activity to brown adipose tissue increases in cold-tolerant mice. Physiol Behav 55:921-925
85. Flier JS, Cook KS, Usher P, Spiegelman BM 1987 Severely impaired adipsin expression in genetic and acquired obesity. Science 237:405-408
86. Kahn BB 1992 Facilitative glucose transporters: regulatory mechanisms and dysregulation in diabetes. J Clin Invest 89:1367-1374
87. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, Speizer FE 1990 Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 132:501-513
88. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B 2002 Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084-2089
89. Sartipy P, Loskutoff DJ 2003 Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 100:7265-7270
90. Groop LC, Ferrannini E 1993 Insulin action and substrate competition. Baillieres Clin Endocrinol Metab 7:1007-1032
91. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M 2005 Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911-2916
92. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ 2006 Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295-299
93. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F 2002 Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32:3225-3234
94. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M 2005 Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289:E586-590
95. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R 2006 Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91:3165-3170
96. Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C 2006 Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 13:661-662
97. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, Bureau F, Andris F, Leo O 2008 Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 181:4685-4695
98. van der Veer E, Nong Z, O’Neil C, Urquhart B, Freeman D, Pickering JG 2005 Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 97:25-34
99. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H 2007 Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748-1758
100. Stephens JM, Vidal-Puig AJ 2006 An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 17:128-131
101. Romacho T, Azcutia V, Vazquez-Bella M, Matesanz N, Cercas E, Nevado J, Carraro R, Rodriguez-Manas L, Sanchez-Ferrer CF, Peiro C 2009 Extracellular BEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52:2455-2463
102. Martin PR, Shea RJ, Mulks MH 2001 Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 183:1168-1174
103. Preiss J, Handler P 1957 Enzymatic synthesis of nicotinamide mononucleotide. J Biol Chem 225:759-770
104. Revollo JR, Grimm AA, Imai S 2007 The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 23:164-170
105. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Bluher M, Stumvoll M, Fasshauer M 2008 Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 115:13-23
106. Pontiroli AE, Pizzocri P, Librenti MC, Vedani P, Marchi M, Cucchi E, Orena C, Paganelli M, Giacomelli M, Ferla G, Folli F 2002 Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 87:3555-3561
107. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP, Liao EY 2007 Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80:201-210
108. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ, 3rd, McGehee RE, Jr., Fried SK, Kern PA 2007 Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 92:666-672
109. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, Hudson TJ, Bouchard C, Gaudet D, Perusse L, Vohl MC, Engert JC 2006 Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55:2896-2902
110. مریم ف 1388 بررسی سطح سرمی ویسفاتین در بیماران مبتلا به سندروم متابولیک. مجله غدد درون ریز و متابولیسم ایران 11:151-157
111. Blakemore AI, Meyre D, Delplanque J, Vatin V, Lecoeur C, Marre M, Tichet J, Balkau B, Froguel P, Walley AJ 2009 A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity (Silver Spring) 17:1549-1553
112. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H, Kilinc M 2009 Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 139:22-27
113. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Silva C, Rotellar F, Cienfuegos JA, Salvador J, Fruhbeck G 2011 Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis 21:245-253
114. Stofkova A 2010 Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 44:25-36
115. Wang Z, Nakayama T 2010 Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010:535918
116. Ghanbari-Niaki A, Saghebjoo M, Soltani R, Kirwan JP 2010 Plasma visfatin is increased after high-intensity exercise. Ann Nutr Metab 57:3-8
117. Jurimae J, Ramson R, Maestu J, Purge P, Jurimae T, Arciero PJ, von Duvillard SP 2009 Plasma visfatin and ghrelin response to prolonged sculling in competitive male rowers. Med Sci Sports Exerc 41:137-143
118. Jorge ML, de Oliveira VN, Resende NM, Paraiso LF, Calixto A, Diniz AL, Resende ES, Ropelle ER, Carvalheira JB, Espindola FS, Jorge PT, Geloneze B 2011 The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus. Metabolism 60:1244-1252
119. Lee KJ, Shin YA, Lee KY, Jun TW, Song W 2010 Aerobic exercise training-induced decrease in plasma visfatin and insulin resistance in obese female adolescents. Int J Sport Nutr Exerc Metab 20:275-281
120. Domieh AM KA 2010 Effect of 8 weeks endurance training on plasma visfatin in middle-aged men. Brazilian Journal of Biomotricity 4:174-179
121. Aldhahi W, Hamdy O 2003 Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 3:293-298
122. Guang Sun JB, Sammy Khalili, Sudesh Vasdev, Vicki Gill, David Pace, Donald Fitzpatrick,, Edward Randell Y-GX, and Hongwei Zhang 2007 Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men American Society for Nutrition:399–404
123. Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Bluher S, Reinehr T, Stumvoll M, Bluher M, Kiess W, Korner A 2011 Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 54:1200-1211
124. Revollo JR, Grimm AA, Imai S 2004 The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279:50754-50763
125. Y. W, HW. W, J. W, HL. L, XF. H, K. C 2006 Effects of fatty acid regulation on visfatin gene expression in adipocyte. Chin Med J (Engl) 119:1701-1708
126. Yan JJ, Tang NP, Tang JJ, Jia EZ, Wang MW, Wang QM, Zhu J, Yang ZJ, Wang LS,

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *